Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

Sherif Farag, Kati Maharry, Mei Jie Zhang, Waleska S. Pérez, Stephen L. George, Krzysztof Mrózek, John DiPersio, Donald W. Bunjes, Guido Marcucci, Maria R. Baer, Mitchell Cairo, Edward Copelan, Corey S. Cutler, Luis Isola, Hillard M. Lazarus, Mark R. Litzow, David I. Marks, Olle Ringdén, David A. Rizzieri, Robert Soiffer & 4 others Richard A. Larson, Martin S. Tallman, Clara D. Bloomfield, Daniel J. Weisdorf

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

We compared the outcomes of patients age 60-70 years with acute myelogenous leukemia receiving reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in first remission (CR1) reported to the Center for International Blood and Marrow Research (n = 94) with the outcomes in patients treated with induction and postremission chemotherapy on Cancer and Leukemia Group B protocols (n = 96). All patients included had been in CR1 for at least 4 months. The HCT recipients were slightly younger than the chemotherapy patients (median age, 63 years vs 65 years; P <.001), but there were no significant between-group differences in the proportion with therapy-related leukemia or in different cytogenetic risk groups. Time from diagnosis to CR1 was longer for the HCT recipients (median, 44 days vs 38 days; P =.031). Allogeneic HCT was associated with significantly lower risk of relapse (32% vs 81% at 3 years; P <.001), higher nonrelapse mortality (36% vs 4% at 3 years; P <.001), and longer leukemia-free survival (32% vs 15% at 3 years; P =.001). Although overall survival was longer for HCT recipients, the difference was not statistically significant (37% vs 25% at 3 years; P =.08). Our findings suggest that reduced-intensity conditioning allogeneic HCT in patients age 60-70 with acute myelogenous leukemia in CR1 reduces relapse and improves leukemia-free survival. Strategies that reduce nonrelapse mortality may yield significant improvements in overall survival.

Original languageEnglish
Pages (from-to)1796-1803
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume17
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Cell Transplantation
Acute Myeloid Leukemia
Drug Therapy
Leukemia
Survival
Recurrence
Induction Chemotherapy
Mortality
Cytogenetics
Bone Marrow
Research
Neoplasms

Keywords

  • Acute myeloid leukemia
  • Allogeneic
  • Chemotherapy
  • Reduced-intensity

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. / Farag, Sherif; Maharry, Kati; Zhang, Mei Jie; Pérez, Waleska S.; George, Stephen L.; Mrózek, Krzysztof; DiPersio, John; Bunjes, Donald W.; Marcucci, Guido; Baer, Maria R.; Cairo, Mitchell; Copelan, Edward; Cutler, Corey S.; Isola, Luis; Lazarus, Hillard M.; Litzow, Mark R.; Marks, David I.; Ringdén, Olle; Rizzieri, David A.; Soiffer, Robert; Larson, Richard A.; Tallman, Martin S.; Bloomfield, Clara D.; Weisdorf, Daniel J.

In: Biology of Blood and Marrow Transplantation, Vol. 17, No. 12, 12.2011, p. 1796-1803.

Research output: Contribution to journalArticle

Farag, S, Maharry, K, Zhang, MJ, Pérez, WS, George, SL, Mrózek, K, DiPersio, J, Bunjes, DW, Marcucci, G, Baer, MR, Cairo, M, Copelan, E, Cutler, CS, Isola, L, Lazarus, HM, Litzow, MR, Marks, DI, Ringdén, O, Rizzieri, DA, Soiffer, R, Larson, RA, Tallman, MS, Bloomfield, CD & Weisdorf, DJ 2011, 'Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission', Biology of Blood and Marrow Transplantation, vol. 17, no. 12, pp. 1796-1803. https://doi.org/10.1016/j.bbmt.2011.06.005
Farag, Sherif ; Maharry, Kati ; Zhang, Mei Jie ; Pérez, Waleska S. ; George, Stephen L. ; Mrózek, Krzysztof ; DiPersio, John ; Bunjes, Donald W. ; Marcucci, Guido ; Baer, Maria R. ; Cairo, Mitchell ; Copelan, Edward ; Cutler, Corey S. ; Isola, Luis ; Lazarus, Hillard M. ; Litzow, Mark R. ; Marks, David I. ; Ringdén, Olle ; Rizzieri, David A. ; Soiffer, Robert ; Larson, Richard A. ; Tallman, Martin S. ; Bloomfield, Clara D. ; Weisdorf, Daniel J. / Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. In: Biology of Blood and Marrow Transplantation. 2011 ; Vol. 17, No. 12. pp. 1796-1803.
@article{4172b5a074694af499f9e1509712d5e3,
title = "Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission",
abstract = "We compared the outcomes of patients age 60-70 years with acute myelogenous leukemia receiving reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in first remission (CR1) reported to the Center for International Blood and Marrow Research (n = 94) with the outcomes in patients treated with induction and postremission chemotherapy on Cancer and Leukemia Group B protocols (n = 96). All patients included had been in CR1 for at least 4 months. The HCT recipients were slightly younger than the chemotherapy patients (median age, 63 years vs 65 years; P <.001), but there were no significant between-group differences in the proportion with therapy-related leukemia or in different cytogenetic risk groups. Time from diagnosis to CR1 was longer for the HCT recipients (median, 44 days vs 38 days; P =.031). Allogeneic HCT was associated with significantly lower risk of relapse (32{\%} vs 81{\%} at 3 years; P <.001), higher nonrelapse mortality (36{\%} vs 4{\%} at 3 years; P <.001), and longer leukemia-free survival (32{\%} vs 15{\%} at 3 years; P =.001). Although overall survival was longer for HCT recipients, the difference was not statistically significant (37{\%} vs 25{\%} at 3 years; P =.08). Our findings suggest that reduced-intensity conditioning allogeneic HCT in patients age 60-70 with acute myelogenous leukemia in CR1 reduces relapse and improves leukemia-free survival. Strategies that reduce nonrelapse mortality may yield significant improvements in overall survival.",
keywords = "Acute myeloid leukemia, Allogeneic, Chemotherapy, Reduced-intensity",
author = "Sherif Farag and Kati Maharry and Zhang, {Mei Jie} and P{\'e}rez, {Waleska S.} and George, {Stephen L.} and Krzysztof Mr{\'o}zek and John DiPersio and Bunjes, {Donald W.} and Guido Marcucci and Baer, {Maria R.} and Mitchell Cairo and Edward Copelan and Cutler, {Corey S.} and Luis Isola and Lazarus, {Hillard M.} and Litzow, {Mark R.} and Marks, {David I.} and Olle Ringd{\'e}n and Rizzieri, {David A.} and Robert Soiffer and Larson, {Richard A.} and Tallman, {Martin S.} and Bloomfield, {Clara D.} and Weisdorf, {Daniel J.}",
year = "2011",
month = "12",
doi = "10.1016/j.bbmt.2011.06.005",
language = "English",
volume = "17",
pages = "1796--1803",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

AU - Farag, Sherif

AU - Maharry, Kati

AU - Zhang, Mei Jie

AU - Pérez, Waleska S.

AU - George, Stephen L.

AU - Mrózek, Krzysztof

AU - DiPersio, John

AU - Bunjes, Donald W.

AU - Marcucci, Guido

AU - Baer, Maria R.

AU - Cairo, Mitchell

AU - Copelan, Edward

AU - Cutler, Corey S.

AU - Isola, Luis

AU - Lazarus, Hillard M.

AU - Litzow, Mark R.

AU - Marks, David I.

AU - Ringdén, Olle

AU - Rizzieri, David A.

AU - Soiffer, Robert

AU - Larson, Richard A.

AU - Tallman, Martin S.

AU - Bloomfield, Clara D.

AU - Weisdorf, Daniel J.

PY - 2011/12

Y1 - 2011/12

N2 - We compared the outcomes of patients age 60-70 years with acute myelogenous leukemia receiving reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in first remission (CR1) reported to the Center for International Blood and Marrow Research (n = 94) with the outcomes in patients treated with induction and postremission chemotherapy on Cancer and Leukemia Group B protocols (n = 96). All patients included had been in CR1 for at least 4 months. The HCT recipients were slightly younger than the chemotherapy patients (median age, 63 years vs 65 years; P <.001), but there were no significant between-group differences in the proportion with therapy-related leukemia or in different cytogenetic risk groups. Time from diagnosis to CR1 was longer for the HCT recipients (median, 44 days vs 38 days; P =.031). Allogeneic HCT was associated with significantly lower risk of relapse (32% vs 81% at 3 years; P <.001), higher nonrelapse mortality (36% vs 4% at 3 years; P <.001), and longer leukemia-free survival (32% vs 15% at 3 years; P =.001). Although overall survival was longer for HCT recipients, the difference was not statistically significant (37% vs 25% at 3 years; P =.08). Our findings suggest that reduced-intensity conditioning allogeneic HCT in patients age 60-70 with acute myelogenous leukemia in CR1 reduces relapse and improves leukemia-free survival. Strategies that reduce nonrelapse mortality may yield significant improvements in overall survival.

AB - We compared the outcomes of patients age 60-70 years with acute myelogenous leukemia receiving reduced-intensity allogeneic hematopoietic cell transplantation (HCT) in first remission (CR1) reported to the Center for International Blood and Marrow Research (n = 94) with the outcomes in patients treated with induction and postremission chemotherapy on Cancer and Leukemia Group B protocols (n = 96). All patients included had been in CR1 for at least 4 months. The HCT recipients were slightly younger than the chemotherapy patients (median age, 63 years vs 65 years; P <.001), but there were no significant between-group differences in the proportion with therapy-related leukemia or in different cytogenetic risk groups. Time from diagnosis to CR1 was longer for the HCT recipients (median, 44 days vs 38 days; P =.031). Allogeneic HCT was associated with significantly lower risk of relapse (32% vs 81% at 3 years; P <.001), higher nonrelapse mortality (36% vs 4% at 3 years; P <.001), and longer leukemia-free survival (32% vs 15% at 3 years; P =.001). Although overall survival was longer for HCT recipients, the difference was not statistically significant (37% vs 25% at 3 years; P =.08). Our findings suggest that reduced-intensity conditioning allogeneic HCT in patients age 60-70 with acute myelogenous leukemia in CR1 reduces relapse and improves leukemia-free survival. Strategies that reduce nonrelapse mortality may yield significant improvements in overall survival.

KW - Acute myeloid leukemia

KW - Allogeneic

KW - Chemotherapy

KW - Reduced-intensity

UR - http://www.scopus.com/inward/record.url?scp=80054717791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054717791&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.06.005

DO - 10.1016/j.bbmt.2011.06.005

M3 - Article

VL - 17

SP - 1796

EP - 1803

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -